Important update: Medically accepted indication edit

Diagnosis requirements for glucagon-like peptide-1 (GLP-1) agonists:

Effective 6/1/2023, Humana will require pharmacies to enter a diagnosis code for a medically accepted indication supplied by the prescriber when processing a prescription claim for a GLP-1 receptor agonist for Humana-covered patients. Beginning on the above date, please include the diagnosis on the GLP-1 prescription to minimize delays in dispensing the medication.

GLP-1 agonists are indicated for type 2 diabetes treatment. They also have shown benefits for obesity and weight management treatment. However, weight loss is excluded from coverage on Humana commercial and MAPD/PDP plans, so GLP-1 agonists will not be covered for this use.

GLP-1 agonists currently approved by the U.S. Food and Drug Administration (FDA) for type 2 diabetes mellitus treatment as an adjunct to diet and exercise include:

- Adlyxin® (lixisenatide)
- Bydureon® (exenatide)
- Byetta® (exenatide)
- Mounjaro® (tirzepatide)
- Ozempic® (semaglutide)
- Rybelsus® (semaglutide)
- Trulicity® (dulaglutide)
- Victoza® (liraglutide)

GLP-1 agonists currently approved by the FDA for obesity and chronic weight management treatment as an adjunct to a reduced-calorie diet and increased physical activity include:

- Saxenda® (liraglutide)
- Wegovy® (semaglutide)

Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991, Monday – Friday, 8 a.m. – 8 p.m., Eastern time.

Please see the table below for a list of common International Classification of Diseases, 10th Revision (ICD-10) codes corresponding to the conditions outlined in this communication.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Common ICD-10 codes&lt;sup&gt;1,2&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 2- Diabetes mellitus and other diabetes mellitus conditions</td>
<td>E08.xx, E09.xx, E11.xx, E13.xx</td>
</tr>
</tbody>
</table>

<sup>1</sup>ICD-10 code list is not comprehensive. The coding information in this document is subject to changing requirements and should not be relied upon as official coding or legal advice.

<sup>2</sup>All coding should be considered on a case-by-case basis and supported by medical necessity and appropriate documentation in the medical record.

References:
1. ICD-10-CM created by the National Center for Health Statistics under authorization by the World Health Organization (WHO). WHO is the copyright holder.
2. The American Academy of Professional Coders

NOTE: Medicare Go Live is 6/15/2023. Only for new GLP-1 starts as grandfathering thru 12/31/23. Also, this edit will only present at pharmacy if we do not find diabetes dx in our ~3 year look back and/or there are no other rx claims for diabetes drugs.